Should You Buy Neil Woodford's Fund?

ASK THE EXPERT: Legendary UK equity income fund manager Neil Woodford launches his eponymous fund this month. But should you buy it?

Emma Wall 5 June, 2014 | 9:23AM
Facebook Twitter LinkedIn

Eight months after Neil Woodford announced his shock departure from Invesco Perpetual, investors have a chance to entrust the UK equity income guru with their cash once more. On June 19, CF Woodford Equity Income Fund will open its doors to the public, although Woodford fanatics can pre-order the fund through various fund supermarkets today.

Woodford has promised investors that the new fund’s portfolio will feature many of the names he has held over the last 25 years at Invesco. The new Woodford fund will be targeting a 4% yield with aims to grow the yield to a “high single digit”.

As well as key players investors will be familiar with such as pharmaceutical stocks and tobacco companies there will be an allocation to unlisted equities, particularly with a technology and innovation theme. Unlisted and micro-cap equities is a sector that Woodford feels passionate about and it is widely expected that he will launch a private equity fund in the near future. A second fund launch has been referenced by Woodford himself, although no date or portfolio information has been released.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
British American Tobacco PLC2,594.00 GBP0.00Rating
GlaxoSmithKline PLC1,434.20 GBP0.00Rating
HSBC Holdings PLC447.15 GBP0.00Rating
Invesco UK Eq High Inc UK Inc326.46 GBP0.46Rating
Invesco UK Equity Inc UK Inc1,303.96 GBP0.54Rating

About Author

Emma Wall  is former Senior International Editor for Morningstar